Individualizing Treatment Options in Advanced ER-Positive Breast Cancer
Introduction Advanced ER-Positive BC
Maximizing Time of Tumor Endocrine Sensitivity
Case Study 1
Interactivity Question 1
1st Line Endocrine Therapy in ABC: Choice of ET + /- CDK 4/6 inhibitor
FALCON: Anastrozole vs Fulvestrant in Hormone Receptor-Positive Advanced BC
FALCON Trial Results
FALCON PFS by Patient Subgroups
Case Study 2
Interactive Question 2
MONALEESA-2: Ribociclib Plus Letrozole vs Letrozole in Hormone Receptor-Positive Advanced BC
MONALEESA-2 Results
MONALEESA-2 Safety Profile
MONALEESA-2 Subgroup Analysis
PALOMA-2 Palbociclib Plus Letrozole vs Letrozole Alone
PALOMA-2 Results
PALOMA-2 AE Summary
Case Study 3
Case Study 1 continued
Interactive Question 3
PALOMA-3 Palbociclib Plus Fulvestrant in Premenopausal/Perimenopausal mBC
PALOMA-3 Results
PALOMA-3 Safety Results
PALOMA-3 and SoFEA ESR1 Mutations
ESR1 Mutations PALOMA-3 Results
BOLERO-2: Everolimus Plus Exemestane vs Placebo Plus Exemestane
BOLERO-2 Results
BOLERO-2 Most Common Grade 3/4 AEs
Conclusions/Key Takeaways